NASDAQ:PHIO Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free PHIO Stock Alerts $0.68 -0.05 (-6.85%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.66▼$0.7350-Day Range$0.55▼$1.0852-Week Range$0.50▼$12.27Volume128,707 shsAverage Volume333,691 shsMarket Capitalization$1.66 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Phio Pharmaceuticals alerts: Email Address Phio Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside488.2% Upside$4.00 Price TargetShort InterestBearish7.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 2 Articles This WeekInsider TradingAcquiring Shares$2,275 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($6.26) to ($3.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Phio Pharmaceuticals has a forecasted upside of 488.2% from its current price of $0.68.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.36% of the float of Phio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhio Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phio Pharmaceuticals has recently increased by 283.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHIO. Previous Next 1.6 News and Social Media Coverage News SentimentPhio Pharmaceuticals has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Phio Pharmaceuticals this week, compared to 1 article on an average week.Search Interest10 people have searched for PHIO on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,275.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.77% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($6.26) to ($3.56) per share.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Phio Pharmaceuticals Stock (NASDAQ:PHIO)Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More PHIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHIO Stock News HeadlinesMarch 21, 2024 | finance.yahoo.comPhio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesMarch 13, 2024 | globenewswire.comPhio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity ResearchMarch 28, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 10, 2024 | morningstar.comPhio Pharmaceuticals Corp PHIOMarch 6, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Neurogene (NGNE), Akero Therapeutics (AKRO)March 6, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin DisordersMarch 6, 2024 | globenewswire.comPhio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin DisordersFebruary 14, 2024 | uk.finance.yahoo.comDry Age Related Macular Degeneration Market Report 2024: Global Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030March 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and Phio Pharmaceuticals (PHIO)January 31, 2024 | finance.yahoo.comPhio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological MalignanciesDecember 19, 2023 | msn.comPhio Pharmaceuticals files to sell 4.42M shares of common stock for holdersDecember 7, 2023 | msn.comWhy Phio Pharmaceuticals Stock Is NosedivingDecember 7, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsNovember 10, 2023 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 10, 2023 | msn.comPhio Pharmaceuticals GAAP EPS of -$1.14 beats by $0.29November 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasNovember 3, 2023 | finanznachrichten.dePhio Pharmaceuticals Corp.: Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlNovember 3, 2023 | finance.yahoo.comPhio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlOctober 12, 2023 | finance.yahoo.comPhio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 12, 2023 | finance.yahoo.comPHIO Jumps 91% on Encouraging Preclinical Cancer Drug DataOctober 11, 2023 | marketwatch.comPhio Pharmaceuticals Shares Up 60% on Favorable PH-894 Preclinical DataOctober 11, 2023 | markets.businessinsider.comCrude Oil Down 2.5%; Silk Road Medical Shares PlummetOctober 11, 2023 | msn.comPhio Pharmaceuticals, Exscientia among healthcare moversOctober 11, 2023 | benzinga.comWhy Is Immuno-Oncology Focused Phio Pharmaceuticals Stock Trading Higher Today?October 11, 2023 | finance.yahoo.comPhio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894See More Headlines Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHIO CUSIPN/A CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+488.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.45% Return on Assets-105.30% Debt Debt-to-Equity RatioN/A Current Ratio4.01 Quick Ratio4.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.52 per share Price / Book0.07Miscellaneous Outstanding Shares2,440,000Free Float2,424,000Market Cap$1.66 million OptionableNot Optionable Beta1.49 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Robert J. Bitterman (Age 73)President, CEO & Chairman Comp: $141.46kMs. Caitlin Kontulis (Age 38)VP of Finance & Administration and Secretary Ms. Linda M. MahoneySenior Vice President of DevelopmentKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSEHistogenNASDAQ:HSTOAllarity TherapeuticsNASDAQ:ALLRCyclacel PharmaceuticalsNASDAQ:CYCCClearmind MedicineNASDAQ:CMNDView All CompetitorsInsidersRobert J BittermanBought 2,500 shares on 2/26/2024Total: $2,275.00 ($0.91/share)Robert J BittermanBought 1,000 shares on 6/30/2023Total: $2,880.00 ($2.88/share)Robert L FerraraBought 2,000 shares on 6/14/2023Total: $6,200.00 ($3.10/share)View All Insider Transactions PHIO Stock Analysis - Frequently Asked Questions Should I buy or sell Phio Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHIO shares. View PHIO analyst ratings or view top-rated stocks. What is Phio Pharmaceuticals' stock price target for 2024? 1 equities research analysts have issued 12 month price objectives for Phio Pharmaceuticals' stock. Their PHIO share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 488.2% from the stock's current price. View analysts price targets for PHIO or view top-rated stocks among Wall Street analysts. How have PHIO shares performed in 2024? Phio Pharmaceuticals' stock was trading at $0.76 at the start of the year. Since then, PHIO stock has decreased by 10.5% and is now trading at $0.68. View the best growth stocks for 2024 here. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 176,600 shares, an increase of 283.9% from the February 29th total of 46,000 shares. Based on an average daily trading volume, of 320,500 shares, the short-interest ratio is presently 0.6 days. Currently, 7.4% of the company's shares are short sold. View Phio Pharmaceuticals' Short Interest. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.03. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST). Who are Phio Pharmaceuticals' major shareholders? Phio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gerrit Dispersyn, Robert J Bitterman and Robert L Ferrara. View institutional ownership trends. How do I buy shares of Phio Pharmaceuticals? Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.